l-Arginine therapy in Raynaud's phenomenon?
- 1 June 1992
- journal article
- Published by Springer Nature in International Journal of Clinical and Laboratory Research
- Vol. 21 (2) , 202-203
- https://doi.org/10.1007/bf02591645
Abstract
Sincel-Arginine is the substrate for nitric oxide synthesis by vascular endothelial cells the effects ofl-arginine treatment on the digital vascular response to local stimuli were investigated in patients with primary or secondary Raynaud's phenomenon. After therapy, patients withu Raynaud's phenomenon secondary to systemic sclerosis showed: (1) higher digital vasodilation after local warming, (2) cold-induced digital vasodilation, and (3) increase of plasma levels of tissue-type plasminogen activator.Keywords
This publication has 7 references indexed in Scilit:
- L-arginine-induced hypotensionThe Lancet, 1991
- Plasma levels of tissue‐type plasminogen activator and von Willebrand factor in patient with Raynaud's phenomenonArthritis & Rheumatism, 1991
- L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits.Circulation Research, 1990
- Prolonged improvement of raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapyArthritis & Rheumatism, 1990
- EFFECTS OF ENDOTHELIUM-DERIVED NITRIC OXIDE ON PERIPHERAL ARTERIOLAR TONE IN MANThe Lancet, 1989
- Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factorNature, 1987
- Morphologic Changes in the Digital Arteries of Patients with Progressive Systemic Sclerosis (Scleroderma) and Raynaud PhenomenonMedicine, 1980